{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T15:02:38Z","timestamp":1709650958581},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,18]]},"DOI":"10.7759\/cureus.13429","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T01:54:52Z","timestamp":1613699692000},"source":"Crossref","is-referenced-by-count":2,"title":["Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19)"],"prefix":"10.7759","author":[{"given":"Ranjit","family":"Banwait","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devina","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anamarys","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaibhav","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Abusaada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"COVID-19 Tracker. (2021). Accessed. 02\/14\/2021: https:\/\/www.bing.com\/covid\/local\/unitedstates."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.04.001","article-title":"ACE2: from vasopeptidase to SARS virus receptor","volume":"25","author":"Turner AJ","year":"2004","unstructured":"Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004, 25:291-4. 10.1016\/j.tips.2004.04.001","journal-title":"Trends Pharmacol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-020-01291-4","article-title":"Outcomes in patients with COVID-19 infection taking ACEI\/ARB","volume":"22","author":"Rico-Mesa JS","year":"2020","unstructured":"Rico-Mesa JS, White A, Anderson AS. Outcomes in patients with COVID-19 infection taking ACEI\/ARB. Curr Cardiol Rep. 2020, 22:31. 10.1007\/s11886-020-01291-4","journal-title":"Curr Cardiol Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang L","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020, 8:21. 10.1016\/S2213-2600(20)30116-8","journal-title":"Lancet Respir Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1001-0939.2020.0014","article-title":"Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia","volume":"43","author":"Sun ML","year":"2020","unstructured":"Sun ML, Yang JM, Sun YP, Su GH. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020, 43:219-22. 10.3760\/cma.j.issn.1001-0939.2020.0014","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba K","year":"2005","unstructured":"Kuba K, Imai Y, Rao S, et al.. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005, 11:875-9. 10.1038\/nm1267","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.05.038","article-title":"A meta-analysis of the relationship between renin-angiotensin-aldosterone system inhibitors and COVID-19","volume":"130","author":"Usman MS","year":"2020","unstructured":"Usman MS, Siddiqi TJ, Khan MS, et al.. A meta-analysis of the relationship between renin-angiotensin-aldosterone system inhibitors and COVID-19. Am J Cardiol. 2020, 130:159-61. 10.1016\/j.amjcard.2020.05.038","journal-title":"Am J Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15622","article-title":"Comparative impacts of ACE (angiotensin-converting enzyme) inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality","volume":"76","author":"Zhou F","year":"2020","unstructured":"Zhou F, Liu YM, Xie J, et al.. Comparative impacts of ACE (angiotensin-converting enzyme) inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality. Hypertension. 2020, 76:e15-e7. 10.1161\/HYPERTENSIONAHA.120.15622","journal-title":"Hypertension"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng J","year":"2020","unstructured":"Meng J, Xiao G, Zhang J, et al.. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020, 9:757-60. 10.1080\/22221751.2020.1746200","journal-title":"Emerg Microbes Infect"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of COVID-19","volume":"382","author":"Mancia G","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020, 382:2431-40. 10.1056\/NEJMoa2006923","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson S","year":"2020","unstructured":"Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020, 323:2052-2059. 10.1001\/jama.2020.6775","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mehta N","year":"2020","unstructured":"Mehta N, Kalra A, Nowacki AS, et al.. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020, 5:1020-1026. 10.1001\/jamacardio.2020.1855","journal-title":"JAMA Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa064","article-title":"A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers","author":"Grover A","year":"2020","unstructured":"Grover A, Oberoi M. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Eur Heart J Cardiovasc Pharmacother. 2020, 064. 10.1093\/ehjcvp\/pvaa064","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19","volume":"382","author":"Vaduganathan M","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med. 2020, 382:1653-9. 10.1056\/NEJMsr2005760","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu Y","year":"2020","unstructured":"Liu Y, Yang Y, Zhang C, et al.. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020, 63:364-74. 10.1007\/s11427-020-1643-8","journal-title":"Sci China Life Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2020.04.013","article-title":"Joint HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID-19","volume":"26","author":"Bozkurt B","year":"2020","unstructured":"Bozkurt B, Kovacs R, Harrington B. Joint HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. J Card Fail. 2020, 26:370. 10.1016\/j.cardfail.2020.04.013","journal-title":"J Card Fail"},{"key":"ref17","unstructured":"COVID-19 and the Use of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers. World Health Organization. (2020). Accessed: 06\/22\/2020: https:\/\/www.who.int\/news-room\/commentaries\/detail\/covid-19-and-the-use-of-angiotensin-converting-enzyme-inhibitors-an...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/50980-renin-angiotensin-aldosterone-system-blockers-prior-to-hospitalization-and-their-association-with-clinical-outcomes-in-coronavirus-disease-2019-covid-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:11Z","timestamp":1707507251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/50980-renin-angiotensin-aldosterone-system-blockers-prior-to-hospitalization-and-their-association-with-clinical-outcomes-in-coronavirus-disease-2019-covid-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.13429","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,18]]}}}